1,4-Dihydro-quinoline-3-carboxylic acid derivatives, process for their
申请人:Laboratorie Roger Bellon
公开号:US04292317A1
公开(公告)日:1981-09-29
New 7-dialkylamino-1-substituted-6-halogeno-4-oxo-1,4-dihydroquinoline-3 carboxylic acids of the formula: ##STR1## wherein the R.sub.1 substituent is methyl, ethyl, vinyl or allyl and non-toxic pharmaceutically acceptable acid addition salts thereof. These compounds are useful as antibacterial agents. Also disclosed are processes for preparing the compounds.
Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions
作者:M. Brad Nolt、Zhijian Zhao、Scott E. Wolkenberg
DOI:10.1016/j.tetlet.2008.03.040
日期:2008.5
Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropriate reaction conditions, highly selective reactions at the quinoline 3-, 4-, and 6-position are possible. (C) 2008 Elsevier Ltd. All rights reserved.
KOGA, HIROSHI;ITOH, AKIRA;MURAYAMA, SATOSHI;SUZUE, SEIGO;IRIKURA, TSUTOMU, J. MED. CHEM., 1980, 23, N 12, 1358-1363
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
作者:Sébastien L. Degorce、Bernard Barlaam、Elaine Cadogan、Allan Dishington、Richard Ducray、Steven C. Glossop、Lorraine A. Hassall、Franck Lach、Alan Lau、Thomas M. McGuire、Thorsten Nowak、Gilles Ouvry、Kurt G. Pike、Andrew G. Thomason
DOI:10.1021/acs.jmedchem.6b00519
日期:2016.7.14
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-[(1S)-1-(1-methyl-
已经发现了一系列新型的3-喹啉羧酰胺,并将其优化为共济失调毛细血管扩张突变(ATM)激酶的选择性抑制剂。从适度强力的HTS命中(4),我们确定了诸如6- [6-(甲氧基甲基)-3-吡啶基] -4-[((1 R)-1-(tetrahydro-2 H -pyran-4-酰基)乙基]氨基} -3-喹啉甲酰胺(72)和7-氟-6- [6-(甲氧基甲基)吡啶-3-基] -4-[((1 S)-1-(1-甲基-1)H-吡唑-3-基)乙基]氨基}喹啉-3-羧酰胺(74)作为有效的和高度选择性的ATM抑制剂,具有适合口服的整体ADME特性。72和74构成探测体内ATM抑制作用的出色口头工具。在疾病相关模型中观察到与DSB诱导剂伊立替康联用的疗效。